Rivacor 7 VR-T / DR-T

Rivacor ICDs are small and slim — only 10mm from front to back — with a smooth, elliptical, and body-friendly BIOshape⁴.

• Rivacor ICDs are the smallest, slimmest devices that are approved for 3T full-body MRI scans⁵.

BIOshape eases implantation⁶ and reduces skin pressure⁷.  It helps to lower the risk of skin erosion while increasing patient comfort⁶.

• The smooth, elliptical form facilitates insertion procedures. On average, four out of five implanting physicians rated ‘ease of device insertion’ and ‘securing in the pocket’ as ‘better’ or even ‘much better’ than with preceding models⁸.
• Thinner design and rounded edges reduce skin pressure⁷ and help to lower the risk of skin erosion.
• Over 90% of implanting physicians rated ‘patient comfort’ as ‘better’ or even ‘much better’ in comparison to previous models⁶.

All these benefits are also available with unique DX Technology that provides complete atrial diagnostics with a single lead.

• With DX ICDs, almost four times more likely to detect AT/AF than with a standard single-chamber ICD.^{11, 12, 13, 14}
• Reliable detection and transmission of atrial high-rate episodes (AHRE) with clinically relevant duration (for AHRE ≥1 hour, positive predictive value [PPV] >99.7%).¹⁵ 
• Correct estimation of AF burden with reliable classification of AHRE episodes by their duration.¹⁵
• Incidence of oral anticoagulation (OAC) prescription onset tends to be higher with DX ICDs compared to standard single-chamber ICDs. ¹²

ICD patients face risks associated with increased atrial burden. While atrial arrhythmias are known to be the most frequent cause of inappropriate shocks in transvenous ICDs, they also increase the risk for hospitalisation and can lead to worsening of heart failure.

BIOTRONIK Home Monitoring helps physicians detect AF earlier². It reduces the number of inappropriate shocks by 90%³ and related  hospitalisation rates by 73%³.

• The TRUST trial clearly shows that BIOTRONIK Home Monitoring enables physician evaluation of arrhythmias more than 30 days earlier². This allows physicians to better manage atrial burden¹⁸.
• In ECOST, a randomised study with 433 patients, BIOTRONIK Home Monitoring was highly effective in the long-term prevention of inappropriate shocks. The number of inappropriate shocks was 90% lower as compared to control³.
• As a consequence of reducing inappropriate shocks through BIOTRONIK Home Monitoring, the number of hospitalised patients was significantly reduced by 73%³.

Home Monitoring works via a smartphone-sized, ‘plug in and go’ CardioMessenger Smart mobile unit, which is quick and easy to use¹⁹ and transmits data without any patient involvement.

• BIOTRONIK's 'plug in and go' solution allows for user-friendly system initialisation. Data transmission is completely automatic, not requiring any active patient involvement¹⁹, while the smartphone-sized CardioMessenger Smart transmitter makes BIOTRONIK Home Monitoring a mobile system.
• Daily, system-based transmission checks allow for industry-leading transmission success rates of 85%^20,21.
• 99% of patients agree that BIOTRONIK Home Monitoring is easy to use, while 98% express their complete satisfaction with the system¹⁹.

QuickCheck gives access to patient data typically within 3 to 4 minutes⁶ for more efficient treatment and greater peace of mind for patients.

• QuickCheck provides fast access to patient data. Upon the physician’s request in the Home Monitoring Service Center, data typically becomes available within 3 to 4 minutes⁶.
• Patient device data can be transmitted without patient interaction.
• This allows clinicians to be responsive to patients' needs remotely, while patient satisfaction may be positively influenced by the knowledge that the physician has access to current cardiac device data.
• Immediate clarification and patient reassurance might be complemented by a scheduled visit (for instance, on the next day), reducing the need for spontaneous hospital visits.